Social Media Ideas for Prescription Drugs And Biologics

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...

PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List

By Karla L. Palmer & Charles D. Snow & Mary Bass —

FDA Committee Supports Peptide Compounding: What Comes Next for Compounders, Telehealth Platforms, Med Spas and Others

Key Takeaways At its July 23-24 meeting, the FDA’s Pharmacy Compounding Advisory Committee voted narrowly in favor of adding six of seven discussed peptides to the FDA’s 503A Bulk...

A Prescription for Drug Costs: Inject Transparency and Improve Accessibility

Drug spending continues to grow, but that doesn’t mean that everyone is getting the medicines that they need. A panel at MedCity News’ Bullseye event discussed the evolution of the...

FDA’s Advisory Committee Votes on Peptides: What It Does and Doesn’t Do

A hastily reassembled Pharmacy Compounding Advisory Committee (PCAC) held meetings on July 23 and 24, 2026 to consider whether seven unapproved peptides should be included on an af...

The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List

By Charles D. Snow & Karla L. Palmer & Mary Bass —

FDA committee recommends looser restrictions for several peptides

An FDA committee is recommending the addition of several peptides to the 503A bulk drug substances list.The FDA’s Pharmacy Compounding Advisory Committee, which has faced scrutiny...

340B Rebates 2.0- HRSA Revives Its Pilot Program — and Sets Up a Collision Course With Congress

The Trump administration advances a claims-based rebate model for select 340B drugs as a new bipartisan Senate bill would block it, forcing health systems to track three reform pat...

Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides

Senate and House Lawmakers Unveil Competing 340B Reform Proposals

By Abdie Santiago —

<![CDATA[What FDA's Peptide Decision Means for the Industry]]>

When the Label Lags the Science: Using 505(o)(4) to Compel Labeling Changes

By Sara W. Koblitz —

<![CDATA[FDA's New Frontier: Drug Pricing Enters the Conversation]]>

<![CDATA[FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV,...

<![CDATA[The Current Status of the 340B Program]]>

<![CDATA[When Drug Pricing Becomes Trade Policy]]>

FRIDAY HEALTH REPORT: Peptides sold online without FDA approval may soon be available by prescription

WASHINGTON — An FDA advisory panel is reviewing whether compounding pharmacies should be allowed to manufacture seven specific peptides, which could make them easier to a...

Drug Channels News Roundup, Mid-July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, Wha...

By Bryce Platt, PharmD Summer's in full swing, but the drug channel didn't take a break. What better way to spend the summer than reading about new pharmacy resources in the...

ACI’s 6th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA

The American Conference Institute’s (ACI’s) virtual 6th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA is scheduled to take place from October 20-29, 20...

Amgen results show biosimilars and IRA pricing reshaping drug spend

Two forces now hitting pharma revenues, and both carry direct implications for employer health plans

The Future of 340B: New Bills Offer Competing Solutions to Modernize the 340B Drug Discount Program

<![CDATA[How Can Restricting Compounded Peptides Affect Current Gray Market Users?]]>

FDA approves two autoinjector formulations for Stelara biosimilar

The FDA has approved a pair of prefilled autoinjector formulations for the Stelara biosimilar ustekinumab-kfce, according to a press release from the manufacturer.Ustekinumab-kfce...

<![CDATA[What Would a Category One Designation Mean for Peptides?]]>